Diaziquone (6.75mg /sq m daily for 5 consecutive days or single-dose 26 mg/sq m) has a broad range of activity of diaziquone against primary nervous system tumors and has enhancement effect combined with either 1,3-bis(2-chloroethyl)-1-nitrosourea or procarbazine in athymic mice[1].
| Animal Model: | Homozygous nu/nu BALB/c athymic mice[1] |
| Dosage: | 6.75mg /sq m or 26 mg/sq m |
| Administration: | 6.75mg /sq m daily for 5 consecutive days or single-dose 26 mg/sq m |
| Result: | Showed rapid clearance in the plasma of athymic mice with a half-life of approximately 11.5 min.
Produced significant growth delays.
Produced significant increases in the median growth delay, significant increases in the number of tumor regressions.
|
